Description
Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
Article: Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
€3.03
€3.03
Extended front-line bevacizumab treatment associated with favourable outcome in ovarian cancer
Top
Notifications
